Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 6, 2006, Pages 621-625

  Berntorp, Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bleeding; Factor VIII; Prophylaxis; Von Willebrand disease; Von Willebrand factor concentrates

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

BLEEDING; BLOOD CLOTTING FACTOR DEFICIENCY; CLINICAL PROTOCOL; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEMARTHROSIS; HUMAN; MENORRHAGIA; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; FEMALE; HEMOPHILIA A; HEMORRHAGE; HUMANS; INFANT; MALE; MIDDLE AGED; VON WILLEBRAND DISEASE; VON WILLEBRAND DISEASES;

EID: 33749027736     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-949667     Document Type: Review

References (22)

1. Von Willebrand EA. Hereditär pseudohemofili. Fin Lakaresallsk Handl 1926;68:87-112
2. Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand 1973;238(suppl):1-159
3. Lak M, Peyvandi F, Mannucci P. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000;111:1236-1239
4. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 2004;10(suppl 4):169-176
5. Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P® in von Willebrand disease. Haemophilia 1998;4:33-39
6. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004;10:243-249
7. Federici AB, Castaman G, Thompson A, Berntorp E. Von Willebrand's disease: clinical management. Haemophilia 2006;12(suppl 3):152-158
8. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992;79:3130-3137
9. Berntorp E, Nilsson IM. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease. Vox Sang 1989;56:212-217
10. Mannucci PM, Chediak J, Hanna W, et al. Alphanate Study Group. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002;99:450-456
11. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160-174
12. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-253
13. Castillo R, Escolar G, Monteagudo J, Aznar-Salatti J, Reverter JC, Ordinas A. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion 1997;37:785-790
14. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992;232:25-32
15. Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol 1971;45:120-127
16. Berntorp E, Astermark J, Bookman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003;9(suppl 1):1-4
17. Berntorp E, Perini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005;16(suppl 1): S23-S26
18. Berntorp E, Baghaei F, Holmström M, et al. Long-term Prophylaxis in VWD. The Swedish Experience. The International Society on Thrombosis & Haemostasis XXth Congress (abst 01444) August 6-12, 2005; Sydney, Australia
19. Ahnström J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004;10:689-697
20. Nilsson IM, Bergentz SE, Larsson SA. Surgery in von Willebrand's disease. Ann Surg 1979;190:746-752
21. Berntorp E, Abshire T. The von Willebrand Disease Prophylaxis Network (vWD PN): Exploring a treatment concept. Thromb Res 2006;118(suppl 1):S19-S22
22. Feldman BM, Pai M, Rivard GE, et al. The Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006;4:1228-1236